S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
My wife was skeptical... until I showed her my account balance. (Ad)
Stock market today: Wall Street clings to modest gains and marks another winning week
Dropbox’s stock is a falling knife worth catching
Investing Wizard Who Turned $37K Into $2.7M in Just 4 Years Makes His Next Big Move (Ad)
Novavax’s dispute resolution and upcoming earnings call
Stock ideas from the 2024 Microcap Conference
Investing Wizard Who Turned $37K Into $2.7M in Just 4 Years Makes His Next Big Move (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Warner Bros. Discover: Debt down, profits up, yet questions remain
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
My wife was skeptical... until I showed her my account balance. (Ad)
Stock market today: Wall Street clings to modest gains and marks another winning week
Dropbox’s stock is a falling knife worth catching
Investing Wizard Who Turned $37K Into $2.7M in Just 4 Years Makes His Next Big Move (Ad)
Novavax’s dispute resolution and upcoming earnings call
Stock ideas from the 2024 Microcap Conference
Investing Wizard Who Turned $37K Into $2.7M in Just 4 Years Makes His Next Big Move (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Warner Bros. Discover: Debt down, profits up, yet questions remain
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
My wife was skeptical... until I showed her my account balance. (Ad)
Stock market today: Wall Street clings to modest gains and marks another winning week
Dropbox’s stock is a falling knife worth catching
Investing Wizard Who Turned $37K Into $2.7M in Just 4 Years Makes His Next Big Move (Ad)
Novavax’s dispute resolution and upcoming earnings call
Stock ideas from the 2024 Microcap Conference
Investing Wizard Who Turned $37K Into $2.7M in Just 4 Years Makes His Next Big Move (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Warner Bros. Discover: Debt down, profits up, yet questions remain
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
My wife was skeptical... until I showed her my account balance. (Ad)
Stock market today: Wall Street clings to modest gains and marks another winning week
Dropbox’s stock is a falling knife worth catching
Investing Wizard Who Turned $37K Into $2.7M in Just 4 Years Makes His Next Big Move (Ad)
Novavax’s dispute resolution and upcoming earnings call
Stock ideas from the 2024 Microcap Conference
Investing Wizard Who Turned $37K Into $2.7M in Just 4 Years Makes His Next Big Move (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Warner Bros. Discover: Debt down, profits up, yet questions remain

Ligand Pharmaceuticals (LGND) ESG Score & Sustainability Data

$75.87
+2.31 (+3.14%)
(As of 02/23/2024 ET)

Key ESG Takeaways for Ligand Pharmaceuticals

The key takeaways are AI-generated and highlight the main contributors behind the net impact scores of Ligand Pharmaceuticals. The insights are based on millions of scientific articles, along with the company-specific product and service portfolio.
  • Ligand Pharmaceuticals seems to create the most significant positive value in categories , , and . The largest positive contribution comes from its impact, which is mostly driven by its Antihypertensives (C02), Pneumococcal vaccines, Quinolones, Fosphenytoin, Antifungal medication (D01) , and Bevacizumab products.
  • Ligand Pharmaceuticals uses resources or causes negative impacts mostly in categories , , and . The negative contribution in the impact category seems to be driven mostly by its Codeine, Carfilzomib, Remdesivir, Pneumococcal vaccines, Fosphenytoin, and Frovatriptan succinate products.
  • To improve its net impact, a company can either grow its positive impacts, or reduce its negative impacts. For example, by doubling its Antihypertensives (C02) business, Ligand Pharmaceuticals would improve its net impact ratio by 1 percentage points.

LGND Impact Ratio

Net impact ratio represents the net impact of a company. It is defined as the (positive impacts - negative impacts) / positive impacts. The maximum value for net impact ratio is 100%, representing a theoretical company with no negative impacts. The minimum value is -∞. Net scores depend on the value sets that determine the importance of different impact categories.
+67.9%
The default value set, where each category is given the same weight.

Value Sets Value sets can be used to assess how different stakeholder values or emphasis on certain values might affect the net impact ratio.

Millennials
Value set of millennials (b. 1980 - 1999), based on Upright's annual Impact at Work survey.
+71.5%
Most Wanted Workforce
Value set of the most wanted workforce, based on Upright's annual Impact at Work survey.
+57.4%
Society First
Value set that emphasizes society impacts over other impacts.
-9.6%
Knowledge First
Value set that emphasizes knowledge impacts over other impacts.
+74.3%
Health First
Value set that emphasizes health impacts over other impacts.
+83.7%

Ligand Pharmaceuticals ESG Score + Net Impact Profile

ImpactNegativeScorePositive
+0.91
+0.91
+1.49
+1.49
+0.10
+0.10
-0.01
-0.01
+0.00
-0.00
+0.03
+0.04
+0.01
+0.01
+1.01
+1.01
-0.00
+0.01
+0.01
-1.54
-1.54
-0.91
+6.91
+7.81
-0.10
+1.02
+1.12
+0.00
+0.00
-0.00
+0.03
+0.04
-0.01
+0.42
+0.42
-0.90
-0.88
+0.02
-0.25
-0.24
+0.01
-0.03
-0.03
+0.00
-0.03
-0.03
+0.00
-0.39
-0.39
+0.00

Upright Model Version 0.7.0
ESG Data Last Updated: December 8, 2022


About Upright's Net Impact Model

Upright's Net Impact Data quantifies the holistic value creation and impact of companies. It details both the negative and positive impacts a company has on the environment, health of people, society and knowledge, and forms a net sum of these costs and gains based on the economic costs of each impact category. The data is produced by Upright's Net Impact model, which is a mathematical model of the economy that produces continuously updated estimates of the net impact of companies by means of an information integration algorithm. The data is primarily sourced from the CORE open access database, which contains over 200 million scientific papers. Other sources of data include open databases published by the World Bank, IMF, WHO, OECD, IPCC, CDC and USDA.













Ligand Pharmaceuticals ESG Score - Frequently Asked Questions

How is Ligand Pharmaceuticals doing in terms of sustainability?

According to The Upright Project, which measures holistic value creation and impact of companies, Ligand Pharmaceuticals has a net impact ratio of 67.9%, indicating an overall positive sustainability impact. Ligand Pharmaceuticals seems to create the most significant positive value in the categories of Physical diseases, Taxes, and Mental diseases. Ligand Pharmaceuticals uses resources or causes negative impacts mostly in the categories of Scarce human capital, Physical diseases, and GHG emissions. Learn more on the sustainability of Ligand Pharmaceuticals.


More ESG Stocks and Research Tools

This page (NASDAQ:LGND) was last updated on 2/24/2024 by MarketBeat.com Staff